Abstract
Lamotrigine is thought to act at voltage-sensitive sodium channels to stabilize neuronal membranes and inhibit the release of excitatory amino acid neurotransmitters (e.g. glutamate, aspartate) that are thought to play a role in the generation and spread of epileptic seizures. In placebo-controlled clinical studies, lamotrigine has been shown to be effective in reducing seizure frequency and the number of days with seizures when added to existing antiepileptic drug therapy in adult patients with partial seizures, with or without generalized tonic-clonic seizures, that are not satisfactorily controlled. Lamotrigine has emerged as a first line treatment for bipolar depression, which is an area of weakness for other mood stabilizers, with positive effect for resistant bipolar disorders and rapid cycling bipolar disorders. We review the Literature on the topic with a specific interest on bipolar disorders.
Keywords: Antiepileptic drugs, Bipolar depression, DSM-IV, double-blind maintenance, randomized controlled trials
Letters in Drug Design & Discovery
Title: Lamotrigine as an Effective Treatment for Behavioral Disorders
Volume: 4 Issue: 6
Author(s): Rita Moretti, Paola Torre, Cristina Vilotti and Rodolfo M. Antonello
Affiliation:
Keywords: Antiepileptic drugs, Bipolar depression, DSM-IV, double-blind maintenance, randomized controlled trials
Abstract: Lamotrigine is thought to act at voltage-sensitive sodium channels to stabilize neuronal membranes and inhibit the release of excitatory amino acid neurotransmitters (e.g. glutamate, aspartate) that are thought to play a role in the generation and spread of epileptic seizures. In placebo-controlled clinical studies, lamotrigine has been shown to be effective in reducing seizure frequency and the number of days with seizures when added to existing antiepileptic drug therapy in adult patients with partial seizures, with or without generalized tonic-clonic seizures, that are not satisfactorily controlled. Lamotrigine has emerged as a first line treatment for bipolar depression, which is an area of weakness for other mood stabilizers, with positive effect for resistant bipolar disorders and rapid cycling bipolar disorders. We review the Literature on the topic with a specific interest on bipolar disorders.
Export Options
About this article
Cite this article as:
Rita Moretti , Paola Torre , Cristina Vilotti and Rodolfo M. Antonello , Lamotrigine as an Effective Treatment for Behavioral Disorders, Letters in Drug Design & Discovery 2007; 4 (6) . https://dx.doi.org/10.2174/157018007781387836
DOI https://dx.doi.org/10.2174/157018007781387836 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ectonucleotidases and Nucleotide/Nucleoside Transporters as Pharmacological Targets for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Approaches to Mitochondrial Gene Therapy
Current Gene Therapy Screen-Printed Biosensors in Drug Analysis
Current Pharmaceutical Analysis 5-HT2C Receptor Agonists as Potential Drugs for the Treatment of Obesity
Current Topics in Medicinal Chemistry 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Flavonoids and other Non-alkaloidal Constituents of Genus Erythrina: Phytochemical Review
Combinatorial Chemistry & High Throughput Screening In Vitro Evaluation of Potential Hepatotoxicity Induced by Drugs
Current Pharmaceutical Design Attempted Cell Cycle Induction in Post-Mitotic Neurons Occurs in Early and Late Apoptotic Programs Through Rb, E2F1, and Caspase 3
Current Neurovascular Research Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms
Current Neuropharmacology Role of Positron Emission Tomography for Central Nervous System Involvement in Systemic Autoimmune Diseases: Status and Perspectives
Current Medicinal Chemistry The Hypothalamus and Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Methods to Assess Tissue-Specific Distribution and Metabolism of Drugs
Current Drug Metabolism Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?
Current Medicinal Chemistry Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets The AMPAR Antagonist Perampanel Regulates Neuronal Necroptosis via Akt/GSK3β Signaling After Acute Traumatic Injury in Cortical Neurons
CNS & Neurological Disorders - Drug Targets The Autism Candidate Gene Neurobeachin Encodes a Scaffolding Protein Implicated in Membrane Trafficking and Signaling
Current Molecular Medicine Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery
Current Topics in Medicinal Chemistry Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research